171 related articles for article (PubMed ID: 25008202)
21. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.
Li M; Chen F; Clifton N; Sullivan DM; Dalton WS; Gabrilovich DI; Nefedova Y
Mol Cancer Ther; 2010 Dec; 9(12):3200-9. PubMed ID: 21159606
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
[TBL] [Abstract][Full Text] [Related]
23. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
24. ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956
[TBL] [Abstract][Full Text] [Related]
25. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
Kline MP; Rajkumar SV; Timm MM; Kimlinger TK; Haug JL; Lust JA; Greipp PR; Kumar S
Leukemia; 2007 Jul; 21(7):1549-60. PubMed ID: 17460700
[TBL] [Abstract][Full Text] [Related]
26. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Reuland SN; Goldstein NB; Partyka KA; Cooper DA; Fujita M; Norris DA; Shellman YG
PLoS One; 2011; 6(8):e24294. PubMed ID: 21897876
[TBL] [Abstract][Full Text] [Related]
27. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
[TBL] [Abstract][Full Text] [Related]
28. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
[TBL] [Abstract][Full Text] [Related]
29. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
Preuss E; Hugle M; Reimann R; Schlecht M; Fulda S
J Biol Chem; 2013 Dec; 288(49):35287-96. PubMed ID: 24133218
[TBL] [Abstract][Full Text] [Related]
30. Rapamycin rescues ABT-737 efficacy in small cell lung cancer.
Gardner EE; Connis N; Poirier JT; Cope L; Dobromilskaya I; Gallia GL; Rudin CM; Hann CL
Cancer Res; 2014 May; 74(10):2846-56. PubMed ID: 24614082
[TBL] [Abstract][Full Text] [Related]
31. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
32. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Huang S; Sinicrope FA
Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
[TBL] [Abstract][Full Text] [Related]
33. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.
Mattoo AR; Zhang J; Espinoza LA; Jessup JM
Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
[TBL] [Abstract][Full Text] [Related]
36. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
Jain HV; Meyer-Hermann M
Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
[TBL] [Abstract][Full Text] [Related]
37. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.
Potter DS; Galvin M; Brown S; Lallo A; Hodgkinson CL; Blackhall F; Morrow CJ; Dive C
Mol Cancer Ther; 2016 Jun; 15(6):1248-60. PubMed ID: 27197306
[TBL] [Abstract][Full Text] [Related]
39. YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells.
Woo SM; Min KJ; Seo BR; Seo YH; Jeong YJ; Kwon TK
Mol Cell Biochem; 2017 May; 429(1-2):91-102. PubMed ID: 28120212
[TBL] [Abstract][Full Text] [Related]
40. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
Pandey MK; Gowda K; Doi K; Sharma AK; Wang HG; Amin S
PLoS One; 2013; 8(11):e78570. PubMed ID: 24223823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
